Comparative effectiveness of 3 or 4 doses of mRNA and inactivated whole-virus vaccines against COVID-19 infection, hospitalization and severe outcomes among elderly in Singapore

Comparative effectiveness of 3 or 4 doses of mRNA and inactivated whole-virus vaccines against COVID-19 infection, hospitalization and severe outcomes among elderly in Singapore

Bibliographic Details
Main Authors:	Celine Y. Tan, Calvin J. Chiew, Vernon J. Lee, Benjamin Ong, David Chien Lye, Kelvin Bryan Tan
Format:	Article
Language:	English
Published:	Elsevier 2022-12-01
Series:	The Lancet Regional Health. Western Pacific
Subjects:	COVID-19 SARS-CoV-2 Vaccines mRNA vaccine Inactivated vaccine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666606522002693

Similar Items

Kinetics of the Neutralizing and Spike SARS-CoV-2 Antibodies following the Sinovac Inactivated Virus Vaccine Compared to the Pfizer mRNA Vaccine in Singapore
by: Chin Shern Lau, et al.
Published: (2022-05-01)

The Effect of a Booster Dose mRNA Vaccine on COVID-19 Infection in Kidney Transplant Recipients after Inactivated or Viral Vector Vaccine Immunization
by: Sansanee Thotsiri, et al.
Published: (2022-10-01)

Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3
by: Yu-Jing Fan, et al.
Published: (2021-09-01)

Heterologous vaccination with inactivated vaccine and mRNA vaccine augments antibodies against both spike and nucleocapsid proteins of SARS-CoV-2: a local study in Macao
by: Hoi Man Ng, et al.
Published: (2023-05-01)

Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody
by: Kristi Tsz-Wan Lai, et al.
Published: (2022-04-01)

Corrigendum: Heterologous vaccination with inactivated vaccine and mRNA vaccine augments antibodies against both spike and nucleocapsid proteins of SARS-CoV-2: a local study in Macao
by: Hoi Man Ng, et al.
Published: (2024-02-01)

Antibody response after a booster dose of BNT162B2mRNA and inactivated COVID-19 vaccine
by: Metin Yigit, et al.
Published: (2022-08-01)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
by: Sitthichai Kanokudom, et al.
Published: (2022-01-01)

Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine
by: Jira Chansaenroj, et al.
Published: (2022-07-01)

A COMPREHENSIVE REVIEW OF A RACE OF VACCINATION AGAINST COVID - 19 VIRUS: THE RECENT VACCINES DEVELOPED
by: Maimonah Qasim Yahya, et al.
Published: (2021-09-01)

Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study
by: Vincent Ka Chun Yan, et al.
Published: (2023-12-01)

Risk of thyroid dysfunction associated with mRNA and inactivated COVID-19 vaccines: a population-based study of 2.3 million vaccine recipients
by: Carlos King Ho Wong, et al.
Published: (2022-10-01)

Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis
by: Guihua Tang, et al.
Published: (2018-11-01)

The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review
by: Reese Jalal Ladak, et al.
Published: (2022-05-01)

Combined immunization with inactivated vaccine reduces the dose of live B. abortus A19 vaccine
by: Chuan-Yu He, et al.
Published: (2022-04-01)

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
by: Moe H. Kyaw, et al.
Published: (2023-01-01)

Preparation and evaluation of goose reovirus inactivated vaccine
by: Xiaoyu Niu, et al.
Published: (2017-07-01)

Impact of polio vaccines (oral polio vaccine - OPV or inactivated polio vaccine - IPV) on rotavirus vaccine-associated intussusception
by: Camila Cristina Martini Rodrigues, et al.
Published: (2022-11-01)

Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals
by: Juan Li, et al.
Published: (2021-10-01)

Booster doses of an inactivated F genotype mumps vaccine enhance immunogenicity in mice
by: Seo Yeon Kim, et al.
Published: (2024-03-01)

Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases
by: Nusrat Zahan Rouf, et al.
Published: (2022-12-01)

Use of a fractional dose of inactivated polio vaccine (fIPV) to increase IPV coverage among children under 5 years of age in Somalia
by: Khaliif Nouh, et al.
Published: (2024-03-01)

Vaccination against Borna Disease: Overview, Vaccine Virus Characterization and Investigation of Live and Inactivated Vaccines
by: Ralf Dürrwald, et al.
Published: (2022-12-01)

Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population
by: Porntip Intapiboon, et al.
Published: (2021-11-01)

Countries with similar COVID-19 vaccination rates yet divergent outcomes: are all vaccines created equal?
by: Zaid A. Alhinai, MD, et al.
Published: (2021-09-01)

Vaccine Adverse Events Following COVID-19 Vaccination with Inactivated Vaccines in Zimbabwe
by: Azure Tariro Makadzange, et al.
Published: (2022-10-01)

Comparison of Safety of Different Vaccine Boosters Following Two-Dose Inactivated Vaccines: A Parallel Controlled Prospective Study
by: Zhi-Qiang Lin, et al.
Published: (2022-04-01)

The Immune Efficacy of Inactivated Pseudorabies Vaccine Prepared from FJ-2012ΔgE/gI Strain
by: Qiu-Yong Chen, et al.
Published: (2022-09-01)

Characterization of early immune responses elicited by live and inactivated vaccines against Johne's disease in goats
by: Mostafa Hanafy, et al.
Published: (2023-01-01)

Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against reindeer rabies
by: Irina Matveeva, et al.
Published: (2022-09-01)

An experience of mass administration of fractional dose inactivated polio vaccine through intradermal needle-free injectors in Karachi, Sindh, Pakistan
by: Umar Farooq Bullo, et al.
Published: (2021-01-01)

Effect of dietary inclusion of mannan oligosaccharides on the efficacy of a novel hydrogen peroxide‐inactivated vaccine against Streptococcus agalactiae in Nile tilapia
by: Fernando Carlos Ramos‐Espinoza, et al.
Published: (2024-02-01)

Recombinant E2 protein enhances protective efficacy of inactivated bovine viral diarrhea virus 2 vaccine in a goat model
by: Yao-Chi Chung, et al.
Published: (2018-06-01)

Comparison of Immune Responses between Inactivated and mRNA SARS-CoV-2 Vaccines Used for a Booster Dose in Mice
by: Ning Luan, et al.
Published: (2023-06-01)

T-Cell Responses Induced by an Intradermal BNT162b2 mRNA Vaccine Booster Following Primary Vaccination with Inactivated SARS-CoV-2 Vaccine
by: Ratchanon Sophonmanee, et al.
Published: (2022-09-01)

Analysis of the adverse events following immunization with inactivated quadrivalent influenza vaccine from 2018 to 2020 in Zhejiang province, with a comparison to trivalent influenza vaccine
by: Huakun Lv, et al.
Published: (2021-11-01)

30-Year Development of Inactivated Virus Vaccine in China
by: Jinrong Shi, et al.
Published: (2023-12-01)

One-Year Post-Vaccination Longitudinal Follow-Up of Quantitative SARS-CoV-2 Anti-Spike Total Antibodies in Health Care Professionals and Evaluation of Correlation with Surrogate Neutralization Test
by: Yesim Tuyji Tok, et al.
Published: (2023-02-01)

Protectivity of COVID-19 Vaccines and Its Relationship with Humoral Immune Response and Vaccination Strategy: A One-Year Cohort Study
by: Ferdi Tanir, et al.
Published: (2022-07-01)

A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues
by: Shahad Saif Khandker, et al.
Published: (2021-11-01)